share buyback
Hikma Pharmaceuticals Posts 7% Revenue Growth in 2025, Launches Share Buyback and Leadership Changes
Hikma Pharmaceuticals achieved 7% revenue growth to $3.349 billion in 2025. The firm announced a $250 million share buyback and key leadership changes.